In this issue:
MRD-CR is a viable intermediate end point in MM
MRD model considering MRD dynamics predicts long-term outcomes
NK composition may be a biomarker of response to daratumumab
Personalised dynamic risk assessment based on transcriptional profiling
Cilta-cel outperforms ide-cel in realworld but is more toxic
Sequential CAR T-cell therapy: salvage anti-GPRC5D promising after anti-BCMA
MonumenTAL-1: High and durable responses to talquetamab in RRMM
Myeloma immune evasion may not be due to T-cell dysfunction
Tregs at diagnosis as a biomarker for functionally high-risk disease
ALCYONE: D-VMP improves survival in transplant-ineligible patients
Please login below to download this issue (PDF)